Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00071487 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)
A Phase 2 study, sponsored by Human Genome Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 449
- Enrollment target
NCT00071487 is a Phase 2 study that has completed, run by Human Genome Sciences. The registered enrollment target is 449 participants.
The verdict
NCT00071487, a Phase 2 study, has completed, sponsored by Human Genome Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 449 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of 3 different doses of belimumab, administered in addition to standard therapy, in patients with active SLE disease.
Interventions
- DRUG Placebo
- DRUG Belimumab 1 mg/kg
- DRUG Belimumab 10 mg/kg
- DRUG Belimumab 4 mg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 449 participants |
| Start Date | 2003-10 |
| Est. Completion | 2006-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00071487
The ClinicalTrials.gov registry entry for NCT00071487 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 449 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Human Genome Sciences, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00071487 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00071487 about?
NCT00071487 is a clinical study titled "Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)". The purpose of this study is to evaluate the safety and efficacy of 3 different doses of belimumab, administered in addition to standard therapy, in patients with active SLE disease.
What is the current status of trial NCT00071487?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 449 participants. The study started on 2003-10. Estimated completion is 2006-06.
What interventions are being tested in trial NCT00071487?
The interventions under investigation include: Placebo (DRUG), Belimumab 1 mg/kg (DRUG), Belimumab 10 mg/kg (DRUG), Belimumab 4 mg/kg (DRUG).
Who is sponsoring clinical trial NCT00071487?
This trial is sponsored by Human Genome Sciences, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.